High correlations were observed between NfL324 and the Uman NfL immunoassay and combined with the similar fold increase between Alzheimer’s disease and controls for NfL324 (1.5×) and the ELISA assay (1.4×), suggests that antibodies used by this Uman proprietary assay were likely selected to target these NfL324 regions. Here, NEFL is linked to early-onset autosomal dominant Alzheimer disease.